Research programme: monoclonal antibody therapeutics - AgenusAlternative Names: AGEN 2041; Checkpoint modulator antibodies - 4-Antibody/Ludwig Institute for Cancer Research; Checkpoint modulator antibodies - Agenus/Incyte; CPM antibodies - Agenus/Incyte; Cytotoxic T-lymphocyte antigen 4 inhibitor antibodies - Agenus/Recepta; PDCD 1 protein inhibitor antibodies - Agenus/Recepta
Latest Information Update: 21 Feb 2017
At a glance
- Originator 4-Antibody; Ludwig Institute for Cancer Research
- Developer Agenus; Ludwig Institute for Cancer Research
- Class Monoclonal antibodies
- Mechanism of Action CD223 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; HAVCR2 protein inhibitors; OX40 receptor agonists; PDCD 1 protein inhibitors; TNFRSF18 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer